Clinical trials: Toll-Like Receptors
Inflammation
The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.
The goal of the study is to find out whether a high fat meal increases blood lipids and causes monocyte (white blood cell) activation, and whether blueberry intake at the same meal lessens monocyte activation in healthy people.
- Trial name
- FL89 (NCT01594008)
- Testing
- Breakfast meal with 2 serving equivalents of blueberries, Breakfast meal with 4 serving equivalents of blueberries
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
COVID-19 Respiratory Infection
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients
The aim of the study is to assess the expression of TLR 3, 7, and 9 in the population of peripheral blood mononuclear cells (PBMC) and in B lymphocytes (CD19+), T lymphocytes (CD4+ and CD8+) using flow cytometry in relation to…
- Trial name
- NCT05089110
- Testing
- blood sample
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma.
- Trial name
- NCT06710223
- Testing
- SD-101, Cryotherapy, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Asthma
Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.
Introduction: Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma. TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters (PAMPs).
- Trial name
- NCT02028637
- Testing
- TLRs
- Where
- Spain
- Volunteers
- 59 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Head and Neck Squamous Cell Carcinoma, Breast Cancer
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma
- Trial name
- NCT02643303
- Testing
- Durvalumab, Tremelimumab, Poly-ICLC
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Ludwig Institute for Cancer Research
Healthy Volunteers
First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers
The purpose of this study is to determine the safety, tolerability and distribution and elimination of a novel therapeutic drug when administered to Healthy Volunteers.
- Trial name
- NI-0101-01 (NCT01808469)
- Testing
- Monoclonal antibody
- Where
- Netherlands
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Light Chain Bioscience - Novimmune SA
COVID19
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 Mahmoud ELkazzaz(1),Tamer Haydara(2), Mohamed Abdelaal(3), Abedelaziz Elsayed(4) ,Yousry Abo-amer(5), Hesham Attia(6), Quan…
- Trial name
- Isotretinoin (NCT04353180)
- Testing
- Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment, Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment, Isotretinoin (13 cis retinoic acid ) capsules
- Where
- 2 sites in Egypt
- Volunteers
- 100,000 people
- Sponsor
- Kafrelsheikh University
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Melanoma
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I a dose escalation is performed and the primary objective is the safety of different doses of TLR-dendritic cell (TLR-DC).
- Trial name
- NCT00940004
- Testing
- autologous dendritic cell vaccination
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Lung Diseases
Possible Relation of Toll-Like Receptors and Nitric Oxide to Chronic Lung Disease
The first objective of this study is to determine if increased expression of one or more members of the toll-like receptor (TLR) family of receptors that are found on inflammatory cells (present in the airway) precede development…
- Trial name
- NCT00245167
- Testing
- Tracheal Aspirate Fluid
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Schizophrenia, Mental Disorders
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy.
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Trial name
- PAFIP_TLR (NCT02897167)
- Testing
- Retrospective study of frozen samples, Prospective study of fresh samples
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Tumors or Premalignant Lesions
Hespecta Vaccination in HPV+ Tumors or Malignant Lesions
A phase I study to establish the highest safe dose that induces HPV16 E6-specific T-cell responses, using the highly promising novel therapeutic vaccine concept named: Hespecta (HPV E Six Peptide Conjugated To Amplivant®) to…
- Trial name
- NCT02821494
- Testing
- Hespecta
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Leiden University
COVID-19
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Aerosol Combination therapy of All-trans retinoic acid and Isotretinoin as A novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients better than vaccine : An innovative Treatment Mahmoud…
- Trial name
- Antibodies (NCT04396067)
- Testing
- Aerosolized 13 cis retinoic acid, Aerosolized All trans retinoic acid
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Plaque Psoriasis
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9. These TLR react to complexes of exogenous nucleic acids (as might be encountered during infection) and endogenous…
- Trial name
- 8400-201 (NCT01899729)
- Testing
- IMO-8400 Regimen 1, IMO-8400 Regimen 2, IMO-8400 Regimen 3
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Asthma, Inflammation
Mucins and Toll-like Receptors in Asthma
This study raises two main hypotheses: 1) Asthmatics patients who present with bronchial hypersecretion differ phenotypically from asthmatic patients without hypersecretion and 2) mucins in asthmatic patients with hypersecretion…
- Trial name
- MUCITOLL (NCT02948153)
- Testing
- clinical study
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
The purpose of this study is to evaluate the long-term safety and efficacy of orally administered enpatoran in participants with cutaneous manifestations of lupus erythematosus who have completed the Elowen-1 (MS504908_0001)…
- Trial name
- NCT07840287
- Testing
- Enpatoran
- Where
- 2 sites in United States, Germany
- Volunteers
- 404 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
HIV Infections
Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth
Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens with or without Toll-like Receptor 4 Agonist on HIV Reservoirs in…
- Trial name
- HVRRICANE (NCT04301154)
- Testing
- HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix
- Where
- South Africa
- Volunteers
- 25 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Melanoma
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
- Trial name
- NCT00960752
- Testing
- gp100, R848 gel, MAGE-3
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center